WallStSmart

argenx NV ADR (ARGX)vsMonte Rosa Therapeutics Inc (GLUE)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

argenx NV ADR generates 8312% more annual revenue ($5.92B vs $70.33M). ARGX leads profitability with a 31.7% profit margin vs -186.2%. ARGX earns a higher WallStSmart Score of 73/100 (B).

ARGX

Strong Buy

73

out of 100

Grade: B

Growth: 10.0Profit: 9.5Value: 6.7Quality: 6.0
Piotroski: 3/9Altman Z: 4.92

GLUE

Hold

36

out of 100

Grade: F

Growth: 6.3Profit: 2.0Value: 5.0Quality: 7.5
Piotroski: 6/9Altman Z: 0.02
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ARGXUndervalued (+67.1%)

Margin of Safety

+67.1%

Fair Value

$2537.60

Current Price

$925.70

$1611.90 discount

UndervaluedFair: $2537.60Overvalued

Intrinsic value data unavailable for GLUE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ARGX6 strengths · Avg: 10.0/10
Return on EquityProfitability
32.8%10/10

Every $100 of equity generates 33 in profit

Profit MarginProfitability
31.7%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
31.9%10/10

Strong operational efficiency at 31.9%

Revenue GrowthGrowth
52.1%10/10

Revenue surging 52.1% year-over-year

EPS GrowthGrowth
50.6%10/10

Earnings expanding 50.6% YoY

Altman Z-ScoreHealth
4.9210/10

Safe zone — low bankruptcy risk

GLUE3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
325.8%10/10

Revenue surging 325.8% year-over-year

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Price/BookValuation
2.4x8/10

Reasonable price relative to book value

Areas to Watch

ARGX3 concerns · Avg: 3.0/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
172.1x2/10

Trading at 172.1x book value

GLUE4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$880.99M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-26.4%2/10

ROE of -26.4% — below average capital efficiency

Free Cash FlowQuality
$-42.54M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : ARGX

The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 31.9%. Revenue growth of 52.1% demonstrates continued momentum.

Bull Case : GLUE

The strongest argument for GLUE centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 325.8% demonstrates continued momentum.

Bear Case : ARGX

The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.

Bear Case : GLUE

The primary concerns for GLUE are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

ARGX profiles as a growth stock while GLUE is a hypergrowth play — different risk/reward profiles.

GLUE carries more volatility with a beta of 1.38 — expect wider price swings.

GLUE is growing revenue faster at 325.8% — sustainability is the question.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ARGX scores higher overall (73/100 vs 36/100), backed by strong 31.7% margins and 52.1% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

argenx NV ADR

HEALTHCARE · BIOTECHNOLOGY · USA

argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.

Monte Rosa Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural mechanisms to selectively break down therapeutically relevant proteins. The company is headquartered in Boston, Massachusetts.

Visit Website →

Want to dig deeper into these stocks?